You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR DICLOFENAC EPOLAMINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for diclofenac epolamine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01380353 ↗ Test Uniformity of Transdermal Drug Delivery to Breast Using Diclofenac Epolamine Completed Northwestern University Early Phase 1 2011-06-01 The purpose of this study is to look for ways to improve breast cancer treatment by giving breast cancer drugs through the skin of the breast. The drug used in this study is a diclofenac epolamine patch and is a nonsteroid anti-inflammatory pain reliever. The drug amount that gathers in the breast, after application of a patch to the skin of the breast, will be measured and compared to the amount that is found in the breast when the patch is applied to the skin of the belly.
NCT02132247 ↗ Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries Completed IBSA Institut Biochimique SA Phase 4 2014-05-01 The primary purpose of this study is to determine whether Flector Patch is safe for use in children. The secondary purpose is to assess blood levels of diclofenac, the active ingredient in Flector Patch.
NCT02324270 ↗ Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain Completed Actavis Inc. Phase 3 2014-05-01 To demonstrate the therapeutic efficacy of a generic diclofenac epolamine patch against Flector patch in the treatment of pain in subjects with minor ankle sprain
NCT03145259 ↗ Evaluation of Bioavailability of Diclofenac Dermal Products Completed Food and Drug Administration (FDA) Early Phase 1 2017-04-19 The study will utilize already FDA-approved marketed diclofenac products in healthy adults to generate data for establishing rate of drug delivery comparisons between diclofenac epolamine patches and diclofenac sodium solution in healthy adults and to determine skin concentrations.
NCT03145259 ↗ Evaluation of Bioavailability of Diclofenac Dermal Products Completed University of Maryland Early Phase 1 2017-04-19 The study will utilize already FDA-approved marketed diclofenac products in healthy adults to generate data for establishing rate of drug delivery comparisons between diclofenac epolamine patches and diclofenac sodium solution in healthy adults and to determine skin concentrations.
NCT03145259 ↗ Evaluation of Bioavailability of Diclofenac Dermal Products Completed University of Maryland, Baltimore Early Phase 1 2017-04-19 The study will utilize already FDA-approved marketed diclofenac products in healthy adults to generate data for establishing rate of drug delivery comparisons between diclofenac epolamine patches and diclofenac sodium solution in healthy adults and to determine skin concentrations.
NCT05171673 ↗ Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injury Recruiting IBSA Institut Biochimique SA Phase 3 2021-10-31 A multi-center, prospective, open-label, controlled study of the pharmacokinetics and safety of the LicartTM topical system in pediatric and adult participants with minor soft tissue injuries. 150 male and female participants aged 6-16 and 18-45 with soft tissue injuries meeting the following criteria will be enrolled to evaluate the pharmacokinetics and safety of the Licart topical system in pediatric and adult participants with minor soft tissue injuries over a 14-day treatment course. The analgesic effects will also be evaluated of the topical system in pediatric and adult participants with minor soft tissue injuries over a 14-day treatment course. To collect principal investigator-reported global response to therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for diclofenac epolamine

Condition Name

Condition Name for diclofenac epolamine
Intervention Trials
Breast Cancer 1
Soft Tissue Injuries 1
Ankle Sprain 1
Athletic Injuries 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for diclofenac epolamine
Intervention Trials
Wounds and Injuries 2
Soft Tissue Injuries 2
Sprains and Strains 1
Ankle Injuries 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for diclofenac epolamine

Trials by Country

Trials by Country for diclofenac epolamine
Location Trials
United States 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for diclofenac epolamine
Location Trials
Texas 3
Florida 3
California 2
Virginia 2
Maryland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for diclofenac epolamine

Clinical Trial Phase

Clinical Trial Phase for diclofenac epolamine
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Early Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for diclofenac epolamine
Clinical Trial Phase Trials
Completed 4
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for diclofenac epolamine

Sponsor Name

Sponsor Name for diclofenac epolamine
Sponsor Trials
IBSA Institut Biochimique SA 2
Actavis Inc. 1
Food and Drug Administration (FDA) 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for diclofenac epolamine
Sponsor Trials
Other 3
Industry 3
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.